Divi's Laboratories (DIVISLAB) is a Healthcare sector company on NSE. Latest filed quarter: Q1 FY27, revenue ₹2,323 Cr, net profit ₹590 Cr, EPS ₹3.18.
Dashboard / Healthcare
Divi's Laboratoriesi
DIVISLAB.NS · NSE · ISIN INE000JKTDFO
Next results 16 Oct 2026 Updated 2mo ago 5 of 15 quarters · NSE actuals
Trading priceOPEN
₹5,820.00-2.0%
vs previous close ₹5,940.37
Day high
₹5,969.19
Day low
₹5,744.24
Volume
1.3 Cr
Illustrative price data for this demo. Not real-time and not intended for trading.
Latest quarter
Q1 FY27
30 Jun 2026
Revenue
₹2,323 Cr
+14.7% YoY
Net profit
₹590 Cr
+10.1% YoY
EPS
₹3.18
vs Q1 FY26
Exchange
NSE
Sector
Healthcare
Industry
Active Ingredients
Market cap
₹10,80,577 Cr
ISIN
INE000JKTDFO
NSE symbol
DIVISLAB
BSE scrip
—
Next results
16 Oct 2026
Revenue by quarter
Last 15Net profit by quarter
Last 15Quarter-by-Quarter
15 quarters| Quarter | Period end | Revenue | QoQ | YoY | Net profit | Profit YoY | Op. profit | EPS | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY27 | 30 Jun 2026 | ₹2,323 Cr | -7.4% | +14.7% | ₹590 Cr | +10.1% | ₹1,158 Cr | 3.18 | 23 Jul 2026 |
| Q4 FY26 | 31 Mar 2026 | ₹2,509 Cr | +6.9% | +17.7% | ₹659 Cr | +12.4% | ₹1,293 Cr | 3.55 | 21 May 2026 |
| Q3 FY26 | 31 Dec 2025 | ₹2,347 Cr | +6.4% | +2.2% | ₹624 Cr | +5.0% | ₹1,224 Cr | 3.36 | 17 Feb 2026 |
| Q2 FY26 | 30 Sep 2025 | ₹2,206 Cr | +8.9% | -4.2% | ₹606 Cr | +16.9% | ₹1,188 Cr | 3.26 | 14 Nov 2025 |
| Q1 FY26 | 30 Jun 2025 | ₹2,026 Cr | -4.9% | -1.8% | ₹536 Cr | +24.6% | ₹1,052 Cr | 2.89 | 19 Aug 2025 |
| Q4 FY25 | 31 Mar 2025 | ₹2,131 Cr | -7.2% | -5.7% | ₹586 Cr | +10.4% | ₹1,150 Cr | 3.16 | 16 May 2025 |
| Q3 FY25 | 31 Dec 2024 | ₹2,297 Cr | -0.2% | +27.0% | ₹594 Cr | +65.9% | ₹1,099 Cr | 22.39 | 03 Feb 2025 |
| Q2 FY25 | 30 Sep 2024 | ₹2,302 Cr | +11.6% | +32.4% | ₹518 Cr | +4.5% | ₹1,076 Cr | 19.51 | 09 Nov 2024 |
| Q1 FY25 | 30 Jun 2024 | ₹2,063 Cr | -8.7% | +29.5% | ₹430 Cr | -6.6% | ₹1,013 Cr | 16.18 | 03 Aug 2024 |
| Q4 FY24 | 31 Mar 2024 | ₹2,259 Cr | +24.9% | +36.9% | ₹531 Cr | +11.8% | ₹1,063 Cr | 19.99 | 25 May 2024 |
| Q3 FY24 | 31 Dec 2023 | ₹1,808 Cr | +4.0% | +15.4% | ₹358 Cr | -18.2% | ₹1,053 Cr | 13.50 | 10 Feb 2024 |
| Q2 FY24 | 30 Sep 2023 | ₹1,738 Cr | +9.1% | — | ₹496 Cr | — | ₹973 Cr | 2.67 | 18 Nov 2023 |
| Q1 FY24 | 30 Jun 2023 | ₹1,593 Cr | -3.5% | — | ₹460 Cr | — | ₹903 Cr | 2.48 | 17 Aug 2023 |
| Q4 FY23 | 31 Mar 2023 | ₹1,650 Cr | +5.4% | — | ₹475 Cr | — | ₹932 Cr | 2.56 | 18 May 2023 |
| Q3 FY23 | 31 Dec 2022 | ₹1,566 Cr | — | — | ₹438 Cr | — | ₹859 Cr | 2.36 | 14 Feb 2023 |
Last updated 23 Jul 2026. Season progress: 84 of 114 tracked companies have filed Q4 FY26.
FAQ
About Divi's Laboratories
India Earnings Tracker is a free, live dashboard of quarterly results for 1,000+ listed Indian companies on NSE and BSE. We aggregate revenue, net profit, operating profit, EPS, and YoY/QoQ growth for every reporting quarter, with direct links to the original filing PDFs. No paywall, no broker estimates — only filed, official numbers from the exchanges.